Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. - Wikidata - awgldk - TriplyDB

Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.

Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.

http://www.wikidata.org/entity/Q33972394

about

Autonomic Dysregulation in Multiple Sclerosis Orthostatic Hypotension: Mechanisms, Causes, Management Current pharmacological management of hypotensive syndromes in the elderly.Diagnosing and treating neurogenic orthostatic hypotension in primary care.Neurogenic orthostatic hypotension - management update and role of droxidopa Droxidopa in neurogenic orthostatic hypotension.Validation of a questionnaire for orthostatic hypotension for routine clinical use.Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease.Orthostatic hypotension: pathophysiology, assessment, treatment and the paradox of supine hypertension.The Treatment of Primary Orthostatic Hypotension.Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.Orthostatic hypotension: managing a difficult problem.Implications of Recent Drug Approvals for Older Adults Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension The role of deep brain stimulation in Parkinson's disease: an overview and update on new developments.Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.Progress in the treatment of small fiber peripheral neuropathy.Recent advances in orthostatic hypotension presenting orthostatic dizziness or vertigo.New clinical trials for nonmotor manifestations of Parkinson's disease.Recognition and treatment of autonomic disturbances in Parkinson's disease.Therapeutic approaches in Parkinson's disease and related disorders.Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies.New and emerging medical therapies in Parkinson's disease.Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.Nondopaminergic treatments for Parkinson's disease: current and future prospects.New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study.The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.Multiple system atrophy: insights into a rare and debilitating movement disorder.Multiple System Atrophy - State of the Art.Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension.Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms.Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.

P2860

Q26799341-9AA916E7-101D-4922-BC2F-6AD6E6AC31C8 Q26801811-5F7AD94F-8C22-425A-BD98-9E4CCE3FCC6E Q33165704-169193F8-ADDA-41E6-863D-CCD148154F85 Q33165773-501FCA76-3ECE-43CD-9773-291F9B328690 Q33165870-F8F7B000-6FB0-4118-8AB2-0F969E3E3B97 Q33165878-D96347F8-7917-4546-A3D0-4F327159C5D9 Q33166010-50B67890-0B14-4011-9C24-29913F100C74 Q33166368-4F8CF91A-576E-4D41-95FD-A20F85BA377E Q33167390-DF20913D-FF3B-4167-99FB-DF6185D82387 Q33168147-F3CE695F-69D6-42DD-B380-9713D4DF8B06 Q33667809-106D4AC0-8181-4C4C-94A1-B56919254171 Q34445249-051AAE75-DD0C-4D29-8674-6CE2828B3010 Q34487619-4B74838D-4E23-4259-88A8-727C8E72C1A1 Q35417194-B800720C-DEBD-4508-B7DF-B22B80C26FD9 Q35671396-E6E988F7-8B8A-4954-8672-086EFE70545C Q36107373-3818E552-D985-4067-B053-B4ADCAC6A1FD Q36943826-D0B5F336-5961-4E4E-BE60-BF1FFB56230D Q37025152-A72432E5-D0E1-4610-B475-42C9AC464AFF Q37265850-B84FCB64-8F23-41D8-93F1-D28CE225D64A Q37698671-FB50D1BA-53B9-4E97-AFEB-9DDC5750D593 Q38258228-6AD2479D-7C3C-44EF-BBF6-2AEE07DCB56D Q38307583-DC06C481-D2A6-4CC6-BBDA-3C735058A683 Q38349089-4CF984F1-1906-4E32-855A-B976ADD543C8 Q38570377-A9ABE642-16E7-4A84-94BF-5C922B504753 Q38587090-0DDA440C-2A3B-45B6-941B-D458BBDAE291 Q38594855-A0897FB8-3CF7-4B76-BB11-DA5C3807429A Q38691406-7B74F3E3-92F3-477D-80C9-F8F25C34321A Q38712697-792513DE-7837-44B7-B528-AF897599175A Q38718194-5DDF7113-0A91-4DC8-9C6A-778D2127D04C Q38764011-79D87709-6E35-49DC-8BD4-E507464FBD6C Q38845546-2EECB2E8-0984-4D6D-802C-A15F95D789BF Q39006423-2A26C2A4-AC70-4225-B9A9-C2F57C8D7857 Q39052115-AB0F846B-8B94-4128-8CCF-A8CB974F0D70 Q39066747-0B166638-547C-41A5-911C-B0C35703E3A4 Q39183459-86F27F53-89AF-4F17-8DE5-8E02FB864EC9 Q39220912-ABF69F51-31F4-486B-841B-59085E28D6BD Q39438327-16675C93-01F1-44C5-A6B1-5F76BC9CEEC0 Q40495838-933EF837-379A-40B8-8610-7D4AF2E96A01 Q44746489-9C3A03D7-85B3-4082-8C22-BA03C966BA97 Q47651254-F88AD2A1-DC61-49E3-83F0-D7E011273D6A

P2860

Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.

http://www.wikidata.org/entity/Q33972394

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.

@ast

Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.

@en

type

label

Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.

@ast

Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.

@en

prefLabel

Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.

@ast

Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.

@en

P1433

Q33972394-C086BEAE-4170-4423-8B6F-917928C9A456

P1476

Q33972394-2A12904C-6530-476C-B20A-0D82DC1482F0

P2093

Q33972394-129221EC-0E73-4B22-81CB-8C6102CB0D5B

Q33972394-232887FA-89B6-4DD3-8C11-077D4494D67F

Q33972394-4B70C1A3-A494-47D1-A8CC-5D88C70DAAEE

Q33972394-76B4C27E-0FC9-46A3-93D9-706D60791D22

Q33972394-90C0F395-2C44-4C57-A076-ABAAAD5E62C5

Q33972394-B0BACA76-CF00-4F7E-A135-AC8F4D0F5A8A

Q33972394-B496EAC4-FD14-467D-951C-C7487B3D6111

Q33972394-CE501D02-7EB1-4AB8-8099-4C5D2A57EB5B

Q33972394-FFC219BF-9600-4DD4-B740-77B2D529B339

P2860

Q33972394-006FD25E-E5C0-4722-AF15-D129B41085C8

Q33972394-0A7EA20E-C5AB-407E-99FF-41F44CD66B71

Q33972394-20B35EC3-B8EA-4B38-8154-8D4C41791595

Q33972394-299518D4-A16F-4B98-AE50-C509D3C74A5F

Q33972394-32652461-2CF2-4676-9D11-831A991F5A43

Q33972394-450636A0-78F6-40CF-9AC9-55307EEDE72E

Q33972394-674968B1-3521-4EF2-AA3D-E589D5A5D024

Q33972394-80566C38-109F-46EA-8D70-98EF3B1675A5

Q33972394-823DCCCC-D474-4290-B158-4522EF7A33C9

Q33972394-82A9E173-6D60-4050-BCBC-815CE68DB9D5

P304

Q33972394-A9DCCDCF-7A4C-4E5C-ACA9-409440D1694E

P31

Q33972394-977C5CDF-CD40-42A1-968F-04D07D8688E8

P356

Q33972394-72ADA423-9572-448F-B43B-133FFD7BC750

P407

Q33972394-115B2CCC-B75A-477F-A3A6-6D038917A8E9

P433

Q33972394-E9CAAD71-C090-4CBD-A996-447702446D99

P478

Q33972394-1D09CD6E-45AD-499C-956F-32E16C672595

P50

Q33972394-081D910A-3438-49C2-9C5F-496C3C4EE0FC

P577

Q33972394-6DF62198-41EC-4A24-A9B0-2A0589B5AA3D

P698

Q33972394-CEB6F4F4-F018-4160-B9AF-059B483BAA2E

P921

Q33972394-75D2CDF6-C955-4663-AD75-480D15F4F781

Q33972394-8BD7187F-04ED-4787-9FDA-C52D6445B1D0

Q33972394-C9A597B5-136A-462A-918E-C1B3CCF4CA09

P932

Q33972394-53FD4990-5F0E-426C-A11B-3199D4DF8C45

P356

WNL.0000000000000615

P1433

P1476

Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.

@en

P2093

Christopher J Mathias

http://www.w3.org/2001/XMLSchema#string

Italo Biaggioni

http://www.w3.org/2001/XMLSchema#string

Joe Mauney

http://www.w3.org/2001/XMLSchema#string

L Arthur Hewitt

http://www.w3.org/2001/XMLSchema#string

Michael Feirtag

http://www.w3.org/2001/XMLSchema#string

NOH301 Investigators

http://www.w3.org/2001/XMLSchema#string

Phillip Low

http://www.w3.org/2001/XMLSchema#string

Roy Freeman

http://www.w3.org/2001/XMLSchema#string

Simon Pedder

http://www.w3.org/2001/XMLSchema#string

P2860

Postural hypotension: causes, clinical features, investigation, and management.

Clinical practice. Neurogenic orthostatic hypotension.

Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine.

Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension.

L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.

Mechanisms of pressure natriuresis.

Norepinephrine precursor therapy in neurogenic orthostatic hypotension.

Neurogenic orthostatic hypotension: a pathophysiological approach

Management of neurogenic orthostatic hypotension: an update.

Orthostatic hypotension: evaluation and treatment.

P304

328-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000000615

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Horacio Kaufmann

P577

2014-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24944260

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4115605

http://www.w3.org/2001/XMLSchema#string